News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cytonet GmbH & Co. KG Release: New Study Examining Therapy Option for the Most Severe Metabolic Disorders in Newborns



4/23/2008 9:01:55 AM

WEINHEIM, Germany--(BUSINESS WIRE)--Cytonet GmbH & Co. KG, Germany’s leading cell therapy company, which is based in Weinheim, near Heidelberg, has received approval for conducting a clinical study in another field of indication for its liver cell suspension.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES